Sarepta Therapeutics Inc (NASDAQ: SRPT) is 42.59% higher on its value in year-to-date trading and has touched a low of $55.25 and a high of $159.89 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SRPT stock was last observed hovering at around $141.53 in the last trading session, with the day’s loss setting it -4.03%.
Currently trading at $137.50, the stock is 7.06% and 19.54% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.03 million and changing -2.85% at the moment leaves the stock 22.84% off its SMA200. SRPT registered 11.73% gain for a year compared to 6-month gain of 15.94%. The firm has a 50-day simple moving average (SMA 50) of $11.31 and a 200-day simple moving average (SMA200) of -$21.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 14.11% loss in the last 1 month and extending the period to 3 months gives it a 66.51%, and is 3.94% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.15% over the week and 3.12% over the month.
Sarepta Therapeutics Inc (SRPT) has around 1162 employees, a market worth around $12.86B and $1.10B in sales. Fwd P/E is 13.65. Profit margin for the company is -62.52%. Distance from 52-week low is 148.87% and -14.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.35%).
Sarepta Therapeutics Inc quarterly earnings per share for the current quarter are estimated at $0.01 with sales reaching $385.81M over the same period.The EPS is expected to grow by 151.08% this year, but quarterly earnings will post 31.30% year-over-year. Quarterly sales are estimated to grow 49.30% in year-over-year returns.
565 institutions hold shares in Sarepta Therapeutics Inc (SRPT), with institutional investors hold 92.27% of the company’s shares. The shares outstanding are 93.55M, and float is at 88.00M with Short Float at 5.46%. Institutions hold 88.32% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 8.53 million shares valued at $977.02 million. The investor’s holdings represent 9.69% of the SRPT Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 5.5 million shares valued at $630.26 million to account for 6.25% of the shares outstanding. The other top investors are Janus Henderson Group PLC which holds 5.45 million shares representing 6.19% and valued at over $623.87 million, while Avoro Capital Advisors LLC holds 5.26% of the shares totaling 4.63 million with a market value of $529.99 million.
Sarepta Therapeutics Inc (SRPT) Insider Activity
A total of 8 insider transactions have happened at Sarepta Therapeutics Inc (SRPT) in the last six months, with sales accounting for 1 and purchases happening 7 times. The most recent transaction is an insider purchase by Barry Richard, the company’s Director. SEC filings show that Barry Richard bought 50,000 shares of the company’s common stock on Nov 03 at a price of $78.81 per share for a total of $3.94 million. Following the purchase, the insider now owns 0.14 million shares.
Sarepta Therapeutics Inc disclosed in a document filed with the SEC on Nov 03 that INGRAM DOUGLAS S (President & CEO) bought a total of 25,225 shares of the company’s common stock. The trade occurred on Nov 03 and was made at $79.36 per share for $2.0 million. Following the transaction, the insider now directly holds 0.39 million shares of the SRPT stock.
Still, SEC filings show that on Aug 14, Chambers Michael Andrew (Director) acquired 9,979 shares at an average price of $109.47 for $1.09 million. The insider now directly holds 246,996 shares of Sarepta Therapeutics Inc (SRPT).
Sarepta Therapeutics Inc (SRPT): Who are the competitors?
One of the company’s main competitors (and peers) include Pfizer Inc. (PFE) that is trading -32.70% down over the past 12 months.Banco Santander S.A. ADR (SAN) lies in the list of competitors of the Sarepta Therapeutics Inc and is 5.63% higher over the same period from SRPT
